Q2 2023 · 13F-HR
BAKER BROS. ADVISORS LPholdings as filed
Filed 2023-08-14 · accession 0001104659-23-091343
$17.28B
Reported value
107
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 81181C104 | — | Seagen Inc. | $8.57B | 49.6% | 44,554,162 | Common | SOLE |
| 45337C102 | INCY | Incyte Corporation | $2.25B | 13.0% | 36,178,056 | Common | SOLE |
| 07725L102 | ONC | BeiGene, Ltd. | $2.08B | 12.0% | 11,668,897 | Common | SOLE |
| 004225108 | ACAD | ACADIA Pharmaceuticals Inc. | $1.03B | 5.94% | 42,864,612 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals, Inc. | $356.9M | 2.07% | 1,545,113 | Common | SOLE |
| 09061G101 | BMRN | BioMarin Pharmaceutical Inc. | $330.3M | 1.91% | 3,810,248 | Common | SOLE |
| 45258D105 | IMCR | Immunocore Holdings plc | $151.1M | 0.87% | 2,520,731 | Common | SOLE |
| 46185LAD5 | — | Invitae Corporation | $135.0M | 0.78% | 300,000,000 | Common | SOLE |
| 50015M109 | KOD | Kodiak Sciences Inc. | $119.4M | 0.69% | 17,310,490 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics, Inc. | $110.6M | 0.64% | 2,368,378 | Common | SOLE |
| 04016X101 | ARGX | argenx SE | $109.2M | 0.63% | 280,159 | Common | SOLE |
| 76243J105 | RYTM | Rhythm Pharmaceuticals, Inc. | $107.2M | 0.62% | 6,498,267 | Common | SOLE |
| 76029N106 | REPL | Replimune Group, Inc. | $106.3M | 0.62% | 4,578,280 | Common | SOLE |
| 00288U106 | ABCL | AbCellera Biologics Inc. | $106.3M | 0.62% | 16,450,180 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $100.6M | 0.58% | 4,375,340 | Common | SOLE |
| G76279101 | ROIV | Roivant Sciences Ltd. | $95.0M | 0.55% | 9,428,592 | Common | SOLE |
| 09058V103 | BCRX | BioCryst Pharmaceuticals, Inc. | $89.5M | 0.52% | 12,710,818 | Common | SOLE |
| 85205L107 | SWTXUSD | SpringWorks Therapeutics, Inc. | $78.7M | 0.46% | 2,999,846 | Common | SOLE |
| 29384C108 | TRDA | Entrada Therapeutics, Inc. | $73.7M | 0.43% | 4,865,819 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $72.0M | 0.42% | 2,691,493 | Common | SOLE |
| N44445109 | IMTX | Immatics N.V. | $65.1M | 0.38% | 5,640,816 | Common | SOLE |
| 16961L106 | — | Chinook Therapeutics, Inc. | $55.9M | 0.32% | 1,455,202 | Common | SOLE |
| 60468T105 | MRTXEUR | Mirati Therapeutics, Inc. | $50.9M | 0.29% | 1,409,784 | Common | SOLE |
| 23345J104 | — | DICE Therapeutics, Inc. | $48.1M | 0.28% | 1,035,786 | Common | SOLE |
| 09077A106 | BMEA | Biomea Fusion, Inc. | $46.3M | 0.27% | 2,108,949 | Common | SOLE |
| 74065P101 | PRLD | Prelude Therapeutics Inc. | $45.6M | 0.26% | 10,123,824 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc. | $42.9M | 0.25% | 1,455,322 | Common | SOLE |
| G5269C101 | — | Kiniksa Pharmaceuticals, Ltd. | $39.6M | 0.23% | 2,809,577 | Common | SOLE |
| 157085101 | CERS | Cerus Corporation | $39.5M | 0.23% | 16,067,558 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics, Inc. | $38.8M | 0.22% | 3,882,125 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc. | $36.1M | 0.21% | 783,059 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics, Inc. | $33.7M | 0.19% | 1,963,479 | Common | SOLE |
| 449585108 | 1K0 | IGM Biosciences, Inc. | $29.1M | 0.17% | 3,157,210 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc. | $28.9M | 0.17% | 751,639 | Common | SOLE |
| 45253H101 | IMGNEUR | ImmunoGen, Inc. | $28.7M | 0.17% | 1,520,097 | Common | SOLE |
| 23306J101 | — | DBV Technologies S.A. | $27.8M | 0.16% | 14,614,264 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics, Inc. | $26.6M | 0.15% | 1,416,530 | Common | SOLE |
| 901384107 | TSVT* | 2seventy bio, Inc. | $25.3M | 0.15% | 2,497,526 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA Biosciences, Inc. | $25.0M | 0.14% | 1,062,123 | Common | SOLE |
| 86150R107 | STOK | Stoke Therapeutics, Inc. | $22.6M | 0.13% | 2,130,238 | Common | SOLE |
| 088786108 | BCYC | Bicycle Therapeutics plc | $21.5M | 0.12% | 843,814 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics, Inc. | $20.7M | 0.12% | 3,023,951 | Common | SOLE |
| 12674W109 | CABA | Cabaletta Bio, Inc. | $20.6M | 0.12% | 1,594,000 | Common | SOLE |
| 501147102 | KRYS | Krystal Biotech, Inc. | $20.0M | 0.12% | 169,934 | Common | SOLE |
| 86627T108 | SMMT | Summit Therapeutics Inc. | $15.8M | 0.09% | 6,304,705 | Common | SOLE |
| 032724106 | ANAB | AnaptysBio, Inc. | $15.8M | 0.09% | 775,924 | Common | SOLE |
| 74168J101 | PRME | Prime Medicine, Inc. | $15.1M | 0.09% | 1,028,466 | Common | SOLE |
| 69404D108 | PACB | Pacific Biosciences of California, Inc. | $15.0M | 0.09% | 1,127,782 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics, Inc. | $14.6M | 0.08% | 1,160,117 | Common | SOLE |
| 82835W108 | SPRY | ARS Pharmaceuticals, Inc. | $13.4M | 0.08% | 2,006,451 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals, Inc. | $11.9M | 0.07% | 1,000,000 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $11.9M | 0.07% | 2,000,000 | Common | SOLE |
| 19240Q201 | COGT | Cogent Biosciences, Inc. | $11.6M | 0.07% | 979,600 | Common | SOLE |
| 730541109 | — | POINT Biopharma Global Inc. | $10.6M | 0.06% | 1,169,103 | Common | SOLE |
| 00653A107 | ADAPY | Adaptimmune Therapeutics plc | $10.1M | 0.06% | 10,969,282 | Common | SOLE |
| 46185L103 | NVTA1EUR | Invitae Corporation | $10.0M | 0.06% | 8,881,104 | Common | SOLE |
| 92337C203 | VSTM | Verastem, Inc. | $9.9M | 0.06% | 1,336,485 | Common | SOLE |
| 374163103 | GERN | Geron Corporation | $9.8M | 0.06% | 3,061,224 | Common | SOLE |
| 427746102 | HRTX | Heron Therapeutics, Inc. | $9.4M | 0.05% | 8,131,678 | Common | SOLE |
| 04746L104 | — | Athira Pharma, Inc. | $9.3M | 0.05% | 3,153,807 | Common | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences, Inc. | $8.9M | 0.05% | 799,451 | Common | SOLE |
| 09609G100 | — | bluebird bio, Inc. | $8.2M | 0.05% | 2,499,715 | Common | SOLE |
| 31189P102 | FATE | Fate Therapeutics, Inc. | $8.0M | 0.05% | 1,671,717 | Common | SOLE |
| 019770106 | ALLO | Allogene Therapeutics, Inc. | $7.8M | 0.05% | 1,576,901 | Common | SOLE |
| 68386J208 | OPTEY | Opthea Limited | $7.5M | 0.04% | 2,691,391 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $7.2M | 0.04% | 343,000 | Common | SOLE |
| 89854M101 | TCRX | TScan Therapeutics, Inc. | $7.0M | 0.04% | 2,784,792 | Common | SOLE |
| 00032Q104 | WHWK | Aadi Bioscience, Inc. | $6.8M | 0.04% | 989,928 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics, Inc. | $5.9M | 0.03% | 1,777,435 | Common | SOLE |
| 014442107 | ALEC | Alector, Inc. | $5.8M | 0.03% | 964,851 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics, Inc. | $5.0M | 0.03% | 1,557,630 | Common | SOLE |
| 632307104 | NTRA | Natera, Inc. | $4.9M | 0.03% | 100,000 | Common | SOLE |
| 556099109 | MGNX | MacroGenics, Inc. | $4.8M | 0.03% | 892,579 | Common | SOLE |
| 589492107 | MREO | Mereo BioPharma Group PLC | $4.7M | 0.03% | 3,554,979 | Common | SOLE |
| 03890D108 | VSAREUR | Aravive, Inc. | $4.1M | 0.02% | 3,261,224 | Common | SOLE |
| N01045108 | — | Affimed N.V. | $3.9M | 0.02% | 6,596,830 | Common | SOLE |
| 43906K100 | HOOKGBP | HOOKIPA Pharma Inc. | $3.9M | 0.02% | 4,425,535 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics, Inc. | $3.9M | 0.02% | 500,000 | Common | SOLE |
| 38406L103 | — | Gracell Biotechnologies Inc. | $3.8M | 0.02% | 1,000,000 | Common | SOLE |
| 52187K200 | CYPH | Leap Therapeutics, Inc. | $3.7M | 0.02% | 1,172,175 | Common | SOLE |
| 87424L207 | TLIS | Talis Biomedical Corporation | $3.7M | 0.02% | 7,624,835 | Common | SOLE |
| 15673T100 | IPSC | Century Therapeutics, Inc. | $3.6M | 0.02% | 1,149,340 | Common | SOLE |
| 59045L106 | — | Mersana Therapeutics, Inc. | $3.6M | 0.02% | 1,086,115 | Common | SOLE |
| 04965G109 | BCELUSD | Atreca, Inc. | $3.5M | 0.02% | 3,532,760 | Common | SOLE |
| 64049K104 | — | Neoleukin Therapeutics, Inc. | $3.2M | 0.02% | 3,821,740 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics, Inc. | $3.1M | 0.02% | 500,000 | Common | SOLE |
| 98401F105 | XNCR | Xencor, Inc. | $3.1M | 0.02% | 123,127 | Common | SOLE |
| 45783C101 | — | Instil Bio, Inc. | $2.9M | 0.02% | 5,273,789 | Common | SOLE |
| 87583X109 | TNGX | Tango Therapeutics, Inc. | $2.5M | 0.01% | 750,000 | Common | SOLE |
| 92243G108 | PCVX | Vaxcyte, Inc. | $2.4M | 0.01% | 48,885 | Common | SOLE |
| 00449L102 | 698 | Achilles Therapeutics plc | $2.4M | 0.01% | 2,557,149 | Common | SOLE |
| 92337R101 | VERA | Vera Therapeutics, Inc. | $2.4M | 0.01% | 146,464 | Common | SOLE |
| 74006W108 | — | Praxis Precision Medicines, Inc. | $2.2M | 0.01% | 1,879,915 | Common | SOLE |
| 01626L105 | — | Aligos Therapeutics, Inc. | $2.0M | 0.01% | 2,076,400 | Common | SOLE |
| 69353Y103 | PMVP | PMV Pharmaceuticals, Inc. | $2.0M | 0.01% | 322,024 | Common | SOLE |
| 46565G104 | 5E7 | iTeos Therapeutics, Inc. | $2.0M | 0.01% | 150,346 | Common | SOLE |
| 929033108 | — | Vor Biopharma Inc. | $2.0M | 0.01% | 633,848 | Common | SOLE |
| 483119202 | KALAEUR | Kala Pharmaceuticals, Inc. | $1.7M | 0.01% | 116,213 | Common | SOLE |
| 46489V104 | ISREUR | Perspective Therapeutics, Inc. | $1.5M | 0.01% | 2,319,286 | Common | SOLE |
| 00773J103 | — | Aeglea BioTherapeutics, Inc. | $1.5M | 0.01% | 3,410,106 | Common | SOLE |
| 31572Q808 | FGENEUR | FibroGen, Inc. | $642,827 | 0.00% | 238,084 | Common | SOLE |
| 65487U108 | NKTX | Nkarta, Inc. | $594,211 | 0.00% | 271,329 | Common | SOLE |
| 74365U107 | TARA | Protara Therapeutics, Inc. | $477,214 | 0.00% | 199,671 | Common | SOLE |
| 37186H100 | — | Genetron Holdings Limited | $423,480 | 0.00% | 455,306 | Common | SOLE |
| 344174107 | FHTX | Foghorn Therapeutics Inc. | $316,990 | 0.00% | 45,027 | Common | SOLE |
| 92731L106 | — | Vincerx Pharma, Inc. | $293,253 | 0.00% | 225,579 | Common | SOLE |
| 86889P117 | SRZNW | Surrozen, Inc. | $46,000 | 0.00% | 833,333 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.